dpp-4 inhibitor with glp-1 receptor agonist combination not recommended ada Development of a treatment selection algorithm for SGLT2 and therapies in people type 2 diabetes: a retrospective cohort study It's the first in a

When retatrutide activates GLP-1 receptors in the brain, it reduces appetite and increases feelings of fullness

Have a conversation with your healthcare provider about weight loss medications, how they work, and their potential risks

Clinical research on tirzepatide

Importantly, these trials exhibited a high degree of heterogeneity in terms of the types of substances studied, patient characteristics, and treatment protocols, which posed significant challenges to drawing definitive conclusions

116 demonstrated that the use of dual therapy of metformin, whether with GLP-1RAs or TZDs, was superior to monotherapy in improving hyperandrogenemia in women with PCOS

GLP-1 can act on the central GLP-1 receptors (especially the hypothalamus) and the central satiety center, causing a feeling of satiety and reducing food intake, thus achieving weight loss through appetite suppression